Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer
Jingxia Zhang, Weiyan Shan, Jie Yu, Huan Shi, Qiaoping Xu, Hongkai Shang · 2026
Read Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer by Jingxia Zhang, Weiyan Shan, Jie Yu, Huan Shi, Qiaoping Xu, Hongkai Shang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13454383.txt.
Description
Zhang and colleagues review new blood based tests for ovarian cancer, a disease often found late because early symptoms are vague. Their 2026 review covers liquid biopsy, which means testing tumor material shed into blood or other fluids instead of cutting tissue. The authors survey tumor DNA in blood, whole tumor cells, platelets changed by tumors, small RNA rings, and tiny cell parcels called exosomes.
Tumor DNA in blood can aid diagnosis, guide drugs aimed at BRCA gene faults, and spot tiny amounts of disease left after treatment. Clusters of tumor cells give clues about spread and drug response. Newer signals, such as tumor educated platelets and exosomes, also show promise for diagnosis and outlook. The review is frank about limits: tests vary in method, miss some cases, and need shared standards before clinics can rely on them.
Catalog record
| CREATOR | Jingxia Zhang, Weiyan Shan, Jie Yu, Huan Shi, Qiaoping Xu, Hongkai Shang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |